From: Stakeholder Input
Lemborexant (Dayvigo): CADTH Reimbursement Review: Therapeutic area: Insomnia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Apr.
Copyright Notice
Copyright © 2023 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.